Stoke Therapeutics: STK-002 data to be presented at AAO 2026

Stoke Therapeutics announced two presentations of data for STK-002, an investigational medicine targeting Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting. The company also provided an update on its Phase 1 OSPREY study, with initial safety and efficacy data anticipated in H1 2027.